Mengchao Wei

Mengchao Wei

Auto-generated profile, based on publicly available information

Mengchao Wei

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Wangfujing, Beijing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAdham Sameer A. Bardeesi
Adham Sameer A. Bardeesi
YGYan-Wu Guo
Yan-Wu Guo
KZKun Zhang
Kun Zhang
SYSuntian Yu
Suntian Yu
MWMengchao Wei
Mengchao Wei
HHHui Huang
Hui Huang
A series of clinical trials have confirmed the correlation between vascular calcification (VC) and cardiovascular events and mortality. However, current treatments have little effects on the regression of VC. Potent and illustrative mechanisms have been proven to exist in both bone metabolism and VC, indicating that these two processes share similarities in onset and progression. Multiple osteoblast-like cells and signaling pathways are involved in the process of VC. In this review, we summarized the roles of different osteoblast-like cells and we emphasized on how they communicated and interacted with each other using different signaling pathways. Further studies are needed to uncover the underlying mechanisms and to provide novel therapies for VC.

5 April 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SCShuling Chen
Shuling Chen
ZPZhenwei Peng
Zhenwei Peng
MWMengchao Wei
Mengchao Wei
WLWeifeng Liu
Weifeng Liu
ZDZihao Dai
Zihao Dai
MKMing Kuang
Ming Kuang
Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications. We aimed to estimate the cost-effectiveness of sorafenib and TACE in advanced HCC. A Markov model was constructed in a hypothetical cohort of patients aged 60 years with advanced HCC and Child-Pugh A/B cirrhosis over a 2-year time frame. Three strategies (full or dose-adjusted sorafenib and TACE) were compared in two cost settings: China and the USA. Transition probabilities, utility and costs were extracted from systematic review of 27 articles. Sensitivity analysis and Monte Carlo analysis were conducted. Full and dose-adjusted sorafenib respectively produced 0.435 and 0.482 quality-adjusted life years (QALYs) while TACE produced 0.375 QALYs. The incremental cost-effectiveness ratio (ICER) of full-dose sorafenib versus TACE was $101,028.83/QALY in China whereas full-dose sorafenib is a dominant strategy (ICER of -$1,014,507.20/ QALY) compared with TACE in the USA. Compared to full-dose sorafenib, dose-adjusted sorafenib was the dominant strategy with the negative ICERs in both China (−$132,238.94/QALY) and the USA (−$230,058.09/QALY). However, dose-adjusted sorafenib is not available currently, so full-dose sorafenib should be compared with TACE. As the acceptability curves shown, full-dose sorafenib was the optimal strategy at the accepted thresholds of WTP in these two countries. Specifically, full-dose sorafenib was the cost-effective treatment compared with TACE if a WTP was set above $21,670 in the USA, whereas in China, TACE could be more favorable than full-dose sorafenib if a WTP was set below $10,473. Dose-adjusted sorafenib may be cost-effective compared to full-dose sorafenib or TACE for advanced HCC patients. However, when confining the comparisons between full-dose sorafenib and TACE, full-dose sorafenib was cost-effective for these patients, under the accepted thresholds of WTP.

2 January 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MWMengchao Wei
Mengchao Wei
WYWenjie Yang
Wenjie Yang
YQYi Qiao
Yi Qiao
LMLin Ma
Lin Ma
WXWeifeng Xu
Weifeng Xu
JDJie Dong
Jie Dong
There are inconsistent results pertaining to risk factors for venous thromboembolism (VTE) in patients following urologic surgeries. We attempted to establish a visualization model to shed further light upon this topic. Consequently, a total of 436 patients who were tested for VTE following urologic surgeries were retrospectively enrolled. Least absolute shrinkage and selection operator method (LASSO) method was utilized to determine risk factors for VTE and a subsequent nomogram was constructed. The concordance index (C-index) and calibration curve were utilized to evaluate the nomogram. The results suggested that age, history of smoking, D-dimer levels on the first postoperative day, transfusion volume and body mass index (BMI) were identified as significant risk factors for VTE. The C-index of the nomogram composed of the five variables was 0.747 (95% CI 0.700–0.793) and the calibration plot demonstrated good performance. Therefore, the present nomogram could predict the risk of VTE following urologic surgeries.

31 July 2026 in Medicine
Verified
Journal Article
Open access
MWMengchao Wei
Mengchao Wei
BPBoju Pan
Boju Pan
WYWenjie Yang
Wenjie Yang
WXWeifeng Xu
Weifeng Xu
JDJie Dong
Jie Dong
Transcription factor binding to IGHM enhancer 3 (TFE3) break-apart fluorescence in situ hybridization (FISH) is the gold standard for the diagnosis of Xp11.2 translocation renal cell carcinoma (tRCC). However, FISH is costly and not accessible in all laboratories. We aimed to develop a surrogate immunohistochemical panel to recognize Xp11.2 tRCC. We retrospectively enrolled 84 patients who underwent surgery for renal lesions from September 2017 to August 2022. Both immunohistochemistry and FISH analysis were performed on their specimens. The sensitivity, specificity, and accuracy of each immunohistochemical marker and combinatorial immunohistochemical panels were calculated. A total of 17 patients were diagnosed with Xp11.2 tRCC using FISH. In patients with Xp11.2 tRCC, 77% (13/17), 100% (17/17), 88% (15/17), 88% (15/17), 100% (17/17), and 71% (12/17) were tested positive for AE1/AE3, CD10, P504S, PAX8, TFE3, and vimentin, respectively, while 94% (16/17) were tested negative for cytokeratin 7 (CK7). The immunohistochemical panel combining negative CK7, positive CD10, positive P504S, and positive TFE3 exhibited a sensitivity of 0.824, a specificity of 0.672, and a highest accuracy of 0.702. The immunohistochemical panel combining negative CK7, positive CD10, positive P504S, and positive TFE3 was a potentially useful tool for the diagnosis of Xp11.2 tRCC.